$8.03
-0.40-4.74%
Últ. Act.: Oct 22, 5:50 PM
$8.19
-0.24-2.85%
Xilio Therapeutics (XLO) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.59 | $-0.66 | $-0.74 | $-0.42 |
| Actual | $-0.33 | $-0.58 | $0.81 | $-1.54 |
| Surprise | +44.1% | +12.1% | +209.5% | -266.7% |
| Revenue | ||||
| Estimate | $12.7M | $8.5M | $8.0M | $21.8M |
| Actual | $18.7M | $12.6M | $13.7M | $19.1M |
| Surprise | +46.9% | +48.4% | +71.9% | -12.7% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.86 | $-0.90 |
| Revenue | ||
| Consensus | $4.9M | $4.1M |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $-0.33 | $-0.59 | 44.1 % |
| Q1 | May 12, 2026 | $-0.58 | $-0.66 | 12.1 % |
| Q4 | Mar 23, 2026 | $0.81 | $-0.74 | 209.5 % |
| Q3 | Nov 13, 2025 | $-1.54 | $-0.42 | -266.7 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $18.69M | $12.72M | 46.9 % |
| Q1 | May 12, 2026 | $12.65M | $8.52M | 48.4 % |
| Q4 | Mar 23, 2026 | $13.69M | $7.96M | 71.9 % |
| Q3 | Nov 13, 2025 | $19.07M | $21.85M | -12.7 % |